Johnson & Johnson's pharmaceutical division is expected to carry the company through its fiscal third quarter, but investors may need to brace for a profit miss even if sales come in ahead of estimates.
RBC Capital Markets, an investment bank, forecasts that J&J's fiscal Q3 sales will land about 1% above analyst consensus, led by its Innovative Medicines unit running 1.3% ahead on strength from key drugs including Tremfya, Icotyde, and Darzalex. However, RBC also projects earnings per share (EPS) of $2.55 versus the $2.81 consensus, suggesting that the extra revenue is not translating into bottom-line profit.
What's driving the drug unit's strength?
Innovative Medicines, which includes prescription drugs and vaccines, is J&J's largest segment and has been a reliable growth engine. The company's oncology and immunology portfolios, particularly Darzalex for multiple myeloma and Tremfya for psoriasis, have consistently posted strong sales. The newer drug Icotyde, a treatment for a type of lung cancer, is also ramping up quickly.
Management has said that roughly 17,000 patients were treated with Icotyde in fiscal Q3, with about 60% of them new to treatment. This early uptake has been helped by full US insurance coverage, which removes a common barrier for new therapies. For everyday investors, this signals that the drug could become a meaningful growth contributor in the coming quarters, but it also means higher upfront costs as the company invests in manufacturing and marketing.
Why is profit lagging?
The gap between RBC's sales and EPS forecasts points to several factors. First, the early ramp of Icotyde likely involves significant launch expenses, including research, sales force, and patient support programs. These costs hit the income statement before the drug's revenue reaches full potential.
Second, J&J's MedTech division is facing stubborn headwinds. RBC notes that the hoped-for second-half rebound in MedTech looks softer than expected, due to tougher competition in electrophysiology and pulsed field ablation—procedures used to treat heart rhythm disorders. Additionally, geopolitical tensions are creating ongoing drag, even though procedure volumes are holding up.
Third, RBC flagged that the recent Firefly and Sail acquisitions may not be fully baked into consensus forecasts. Deal-related costs often appear below the sales line, meaning they can depress EPS even when revenue looks healthy.
What it means for investors
For markets, the EPS miss could matter more than the sales beat. A sales beat paired with an EPS miss is usually read as an "earnings quality" issue, not a demand problem. If revenue is running ahead but profit per share is behind, investors tend to assume that incremental margins—how much profit each extra dollar of sales produces—are weaker than expected, or that costs below the operating line are heavier than models assumed.
That's why the market reaction around the Oct. 13th report may hinge less on whether Innovative Medicines tops estimates and more on whether analysts reset forward EPS toward RBC's $2.55 view. If that happens without a matching lift in longer-term profit expectations, J&J's valuation multiple could compress as investors reprice the reliability of its earnings.
For ordinary investors, this is a reminder that a company's top line and bottom line can tell different stories. Even a large, diversified healthcare giant like J&J can see its stock move on profit expectations rather than just sales growth. As with any earnings report, the focus should be on the underlying trends—whether drug sales are sustainable, how MedTech competition is evolving, and whether acquisition costs are one-time or recurring.
Investors may also want to watch how J&J's results compare with other companies facing similar dynamics. For instance, RPM beat profit estimates but trimmed its sales outlook, showing that cost pressures can offset revenue strength. Similarly, Almarai's sales rose 11% but costs capped profit growth, a pattern that echoes J&J's situation.
J&J is scheduled to report its Q3 results on Oct. 13th. Until then, investors will be watching for any updates on Icotyde's uptake, MedTech competition, and whether the company's guidance reflects the headwinds RBC has identified.
